These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16483941)

  • 1. [Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
    Tournigand C; de Gramont A
    Bull Cancer; 2006 Feb; 93 Suppl 1():S11-5. PubMed ID: 16483941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of oxaliplatin in the management of colorectal cancer.
    de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
    Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Figer A; Perez-Staub N; Carola E; Tournigand C; Lledo G; Flesch M; Barcelo R; Cervantes A; André T; Colin P; Louvet C; de Gramont A
    Cancer; 2007 Dec; 110(12):2666-71. PubMed ID: 17963264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
    J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Comella P; Massidda B; Palmeri S; Putzu C; De Rosa V; Izzo F; Fiore F; Casaretti R; Sandomenico C
    Anticancer Drugs; 2006 Sep; 17(8):985-92. PubMed ID: 16940809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Alberts S
    J Clin Oncol; 2006 Jul; 24(21):3347-53. PubMed ID: 16849748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
    Hebbar M; Chibaudel B; André T; Louvet C; Smith D; Mineur L; Bennamoun M; Mabro M; Brusquant D; Bonnetain F; Pruvot FR; de Gramont A
    J Chemother; 2013 Apr; 25(2):104-11. PubMed ID: 23684358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    André T; Tournigand C; Mineur L; Fellague-Chebra R; Flesch M; Mabro M; Hebbar M; Postel Vinay S; Bidard FC; Louvet C; de Gramont A
    Ann Oncol; 2007 Jan; 18(1):77-81. PubMed ID: 17030548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IFL].
    Yamazaki K; Yoshino T; Boku N
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.
    Hebbar M; Chibaudel B; André T; Mineur L; Smith D; Louvet C; Dutel JL; Ychou M; Legoux JL; Mabro M; Faroux R; Auby D; Brusquant D; Khalil A; Truant S; Hadengue A; Dalban C; Gayet B; Paye F; Pruvot FR; Bonnetain F; Landi B; Flesch M; Carola E; Martin P; Vaillant E; de Gramont A;
    Ann Oncol; 2015 Feb; 26(2):340-7. PubMed ID: 25403578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
    J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
    Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
    Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
    J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.